Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Group News | The Ministry of Industry and Information Technology's 2017 Top 100 Chinese Pharmaceutical Companies list has been released, with Lizhu Group ranking 26th.
Published Time：
2018-12-18
(This article is reprinted from Health World Saiberlan)
The list of China's Top 100 Pharmaceutical Companies is out!
On August 4, the 2018 (35th) National Pharmaceutical Industry Information Annual Conference, hosted by the China Pharmaceutical Industry Information Center, opened in Shanghai. Coinciding with the 60th anniversary of the organizer, the China Pharmaceutical Industry Information Center, the conference invited leaders from relevant departments such as the National Health Commission, the National Medical Products Administration, and the National Healthcare Security Administration.
Four domestically produced Class I new drugs have been approved for listing this year.
At the meeting, Cao Xuejun, Deputy Director of the Consumer Goods Industry Department of the Ministry of Industry and Information Technology, introduced that from January to June this year, the added value of the scale-above pharmaceutical industry increased by 11% year-on-year, ranking among the top in the national industrial sector. The main business income of scale-above enterprises increased by 13.2% year-on-year, and the total profit increased by 15.2% year-on-year, maintaining a rapid growth rate and a high profit level.
Since the beginning of this year, more than 130 domestically produced Class I new drugs have been declared for clinical trials, and 4 domestically produced Class I new drugs have been approved for listing, creating the best level in history.
Essential drug list adjustment has caused considerable controversy.
It is understood that the Drug Administration Department of the National Health Commission is drafting a draft for soliciting opinions on "Opinions on Further Improving the National Essential Drug System." According to the draft, the content of this improvement will include dynamically adjusting and optimizing the catalog.
Li Bo, director of the Essential Drug Use Management Office of the Drug Administration Department of the National Health Commission, who attended the meeting, introduced a series of measures taken to reform and improve the supply guarantee mechanism for short-supply drugs. However, no further explanation was given on the adjustment of the essential drug list, which is of concern to the industry.
He said, "Currently, this opinion is still in the process of soliciting opinions, and there are still many controversies. Therefore, it may be further shared at the next meeting."
Academician: We should have confidence in domestically produced vaccines.
In the afternoon's roundtable discussion, Li Song, an academician of the Chinese Academy of Engineering, talked about the recently discussed vaccine issue. He said that we should still have confidence in our country's own vaccines, and the relevant companies should be dealt with accordingly.
Once the public loses confidence in domestically produced vaccines, the consequences will be even more serious. Our country's vaccines have made great achievements in recent years, such as hepatitis B. Our country is known as a major hepatitis B country, but now the carrier rate of hepatitis B virus among children under 5 years old is less than 0.5%, which means that the title of a major hepatitis B country will soon be removed. However, if the immune expansion is once out of control or lost, the consequences will be very serious.
Therefore, our country's vaccines are actually not inferior to international vaccines. Chen Kaixian, an academician of the Chinese Academy of Sciences, also agrees with this view.
China's Top 100 Pharmaceutical Companies list released; four new companies make the list.
The list of the Top 100 Pharmaceutical Companies in China in 2017 was released at the meeting. Yangtze River Pharmaceutical Group Co., Ltd., Guangzhou Pharmaceutical Group Co., Ltd., and Zhengxin Pharmaceutical Group Co., Ltd. ranked among the top three.
According to the statistics and analysis of the China Pharmaceutical Industry Information Center, the companies on the Top 100 list in 2017 continued their strong growth momentum, exceeding the 750 billion yuan mark with a growth rate of 10.2% in main business income. Although the growth rate decreased by 0.9 percentage points year-on-year, the growth trend remained basically stable.
It is worth noting that the threshold for the Top 100 list has also increased from 2.44 billion yuan last year to 2.56 billion yuan, a slight increase of 5%. Driven by the leading companies in the Top 100, the pharmaceutical industry is gradually moving towards economies of scale.
It is worth noting that four companies have become new members of the "Top 100" this time.
The meeting also released the "Top 20 Pharmaceutical R&D Product Line Enterprises in China in 2018, Top 10 Most Growth Potential Pharmaceutical Enterprises in China in 2018, and Top 10 Most Investment Value Pharmaceutical Enterprises (Non-listed) in China in 2018" lists.
Appendix: 2017 List of China's Top 100 Pharmaceutical Companies
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.